This year’s report identifies seven experimental treatments worth keeping an eye on. It also looks at the regulatory and generic impact on the drug landscape of the future.
These therapeutics are likely to achieve blockbuster status by 2026, per Clarivate analysis, and could transform treatment paradigms for the benefit of patients worldwide.
Drugs to Watch identifies treatments entering the market that have potential to realize $1 billion USD annual sales within five years, based on interviews with therapy experts; Disease Landscape & Forecast reports; Cortellis™ sales data; and other industry sources.
The drug innovation landscape is evolving, and many companies are developing platforms to address challenges in delivery and targeting across therapeutic areas.
Find out more about:
“After years of declining R&D productivity, the last five years has seen an increase in approvals of innovative medicines at a rate more than double what it was a decade ago. A number of drivers have aligned to achieve this improvement, including greater insight into the biological roots of diseases, oncology research benefiting from the routine introduction of biomarkers to better target therapies, the emergence of gene and cell therapies and efforts by regulatory agencies to introduce processes to accelerate medicine assessment.”
With more than 240 vaccines and 750+ treatments in development for COVID-19, pharmas continue their efforts to address the pandemic.